Abstract
Not all sarcoidosis patients need treatment. In about 40% of cases, disease will subside spontaneously. For the rest who need to be treated, older drugs like corticosteroids, methotrexate and hydroxychloroquine, as well as the more recent anti-TNF agents, will be effective in suppressing granulomatous inflammation in every organ involved in about 30% of cases. In 20% of the patients, disease will relapse upon discontinuation or tapering of treatment, and in 10% will progress (these two categories constituting chronic disease). In these cases, reinstitution of the same or alternative medication or a combination regimen is warranted. Drugs side-effects and patients comorbidities should be taken in consideration during the selection of the appropriate regimen.
Keywords: Sarcoidosis, treatment, corticosteroids, methotrexate, hydroxychloroquine, infliximab
Current Drug Therapy
Title: A Guide to Treatment of Sarcoidosis
Volume: 5 Issue: 2
Author(s): Ilias C. Papanikolaou, Hidenobu Shigemitsu and Om P. Sharma
Affiliation:
Keywords: Sarcoidosis, treatment, corticosteroids, methotrexate, hydroxychloroquine, infliximab
Abstract: Not all sarcoidosis patients need treatment. In about 40% of cases, disease will subside spontaneously. For the rest who need to be treated, older drugs like corticosteroids, methotrexate and hydroxychloroquine, as well as the more recent anti-TNF agents, will be effective in suppressing granulomatous inflammation in every organ involved in about 30% of cases. In 20% of the patients, disease will relapse upon discontinuation or tapering of treatment, and in 10% will progress (these two categories constituting chronic disease). In these cases, reinstitution of the same or alternative medication or a combination regimen is warranted. Drugs side-effects and patients comorbidities should be taken in consideration during the selection of the appropriate regimen.
Export Options
About this article
Cite this article as:
C. Papanikolaou Ilias, Shigemitsu Hidenobu and P. Sharma Om, A Guide to Treatment of Sarcoidosis, Current Drug Therapy 2010; 5 (2) . https://dx.doi.org/10.2174/157488510791065102
DOI https://dx.doi.org/10.2174/157488510791065102 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of RNA Modifications and RNA-modifying Proteins in Cancer Therapy and Drug Resistance
Current Cancer Drug Targets Targeting Host Cell Proteases to Prevent SARS-CoV-2 Invasion
Current Drug Targets Histone Methyltransferase Inhibitors: Novel Epigenetic Agents for Cancer Treatment
Current Medicinal Chemistry The Role of Connexins in Carcinogenesis: Review of Current Knowledge
Current Signal Transduction Therapy New and Highly Potent Antitumor Natural Products from Marine-Derived Fungi: Covering the Period from 2003 to 2012
Current Topics in Medicinal Chemistry Modulation of Prion by Small Molecules: From Monovalent to Bivalent and Multivalent Ligands
Current Topics in Medicinal Chemistry Diselenides and Selenocyanates as Versatile Precursors for the Synthesis of Pharmaceutically Relevant Compounds
Current Organic Synthesis Automated PET Radiotracer Manufacture on the BG75 System and Imaging Validation Studies of [18F]fluoromisonidazole ([18F]FMISO)
Current Radiopharmaceuticals Thymoquinone Anticancer Discovery: Possible Mechanisms
Current Drug Discovery Technologies Overcoming Drug Resistance by Enhancing Apoptosis of Tumor Cells
Current Cancer Drug Targets Male Pelvic Pain: Beyond Urology and Chronic Prostatitis
Current Rheumatology Reviews Peptide-Receptor Ligands and Multivalent Approach
Anti-Cancer Agents in Medicinal Chemistry Mast Cells in Lung Homeostasis: Beyond Type I Hypersensitivity
Current Respiratory Medicine Reviews Mechanism of Action of Limonene in Tumor Cells: A Systematic Review and Meta-Analysis
Current Pharmaceutical Design Microarrays and Colon Cancer in the Road for Translational Medicine
Current Bioinformatics Inhibitors of HDACs - Effective Drugs Against Cancer?
Current Cancer Drug Targets Activation of B Cells by a Dendritic Cell-Targeted Oral Vaccine
Current Pharmaceutical Biotechnology Knockdown of Insulin-Like Growth Factor I Receptor Inhibits the Growth and Enhances Chemo-Sensitivity of Liver Cancer Cells
Current Cancer Drug Targets Natural Compounds as Antagonists of Canonical Wnt/β-Catenin Signaling
Current Chemical Biology Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin
Current Cancer Drug Targets